Role of N6-methyladenosine methyltransferase component RBM15 in cancer progression and its therapeutic potential DOI Creative Commons

Wenxiang Shen,

Yulong Ma,

Chunwang Yang

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Май 22, 2025

Cancer ranks as a primary cause of mortality globally, and the study its molecular markers regulatory mechanisms holds paramount importance. N6-methyladenosine (m⁶A) represents predominant modification in messenger RNA (mRNA), influencing key biological processes including stability, splicing, translation. The dynamic modulation m⁶A is mediated by an array enzymes comprising methyltransferases ("writers"), demethylases ("erasers"), m⁶A-binding proteins ("readers").As pivotal member "writer" family, binding motif protein 15 (RBM15) facilitates recruitment methyltransferase complex (MTC) to mRNA, thus orchestrating addition modifications. Although prior research has underscored critical role oncogenesis, precise through which RBM15 operates cancer are yet be elucidated. This endeavors elucidate structural characteristics functional roles RBM15, investigate potential across diverse tumors, uncover distinct functions tumor genesis, progression, metastasis, evaluate therapeutic targeting treatment.

Язык: Английский

A Haplotype GWAS in Syndromic Familial Colorectal Cancer DOI Open Access
Litika Vermani, Johanna Samola Winnberg, Wen Liu

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(2), С. 817 - 817

Опубликована: Янв. 19, 2025

A previous genome-wide association study (GWAS) in colorectal cancer (CRC) patients with gastric and/or prostate their families suggested genetic loci a shared risk for these three cancers. second haplotype GWAS was undertaken the same and different controls aim of confirming result finding novel loci. The analysis involved 685 cases 1642 healthy from Sweden. logistic regression model used sliding window approach. Whole-genome exome sequencing datawere to find candidate SNPs be tested nested case-control study. In controls, all ten were confirmed. Fifty p-value < 5 × 10−6 odds ratios between 1.35–6.52. Two 50 loci, on 13q33.3 16q23.3, as or data 122 search variants performed test at 11 cohort 827 familial sub-cohort 293 CRC colorectal, gastric, within 1530 controls. One SNP, rs115943733 10q11.21, reached statistical significance (OR = 3.26, p 0.009). Seven 4 had higher OR smaller compared larger cases. results this gave support an increased CRC, cancer. Further studies are needed confirm able use information prevention.

Язык: Английский

Процитировано

1
Role of N6-methyladenosine methyltransferase component RBM15 in cancer progression and its therapeutic potential DOI Creative Commons

Wenxiang Shen,

Yulong Ma,

Chunwang Yang

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Май 22, 2025

Cancer ranks as a primary cause of mortality globally, and the study its molecular markers regulatory mechanisms holds paramount importance. N6-methyladenosine (m⁶A) represents predominant modification in messenger RNA (mRNA), influencing key biological processes including stability, splicing, translation. The dynamic modulation m⁶A is mediated by an array enzymes comprising methyltransferases ("writers"), demethylases ("erasers"), m⁶A-binding proteins ("readers").As pivotal member "writer" family, binding motif protein 15 (RBM15) facilitates recruitment methyltransferase complex (MTC) to mRNA, thus orchestrating addition modifications. Although prior research has underscored critical role oncogenesis, precise through which RBM15 operates cancer are yet be elucidated. This endeavors elucidate structural characteristics functional roles RBM15, investigate potential across diverse tumors, uncover distinct functions tumor genesis, progression, metastasis, evaluate therapeutic targeting treatment.

Язык: Английский

Процитировано

0